Related Experiment Videos
The use of cardiac markers in acute coronary syndromes
1Roche Diagnostics GmbH, Germany. bhuwnesh.agrawal@roche.com
Insights
Cardiac markers like myoglobin and troponin (especially troponin T) are crucial for managing acute coronary syndromes. Their use improves patient care and offers significant cost savings through efficient management.
Area of Science:
- Cardiology
- Biomarkers
Background:
- Acute coronary syndromes (ACS) require effective diagnostic and management tools.
- Cardiac markers play a vital role in the diagnosis, triage, treatment, and monitoring of ACS patients.
Purpose of the Study:
- To review recent data on the relevance of cardiac markers, particularly myoglobin and troponins, in managing non-ST elevation ACS.
- To evaluate the economic benefits of using cardiac markers in patient management.
Main Methods:
- Review of recent scientific data and economic studies.
- Evaluation of the utility of myoglobin and troponin T (TnT) in ACS management.
Main Results:
- Myoglobin and troponin, especially TnT, are well-suited for ACS management, aligning with NACB and IFCC recommendations.
- Cardiac markers aid in deciding treatment for non-ST elevation ACS.
- Economic studies demonstrate significant cost savings from efficient patient management using these diagnostics.
Conclusions:
- Cardiac markers are valuable tools for managing ACS patients.
- The combination of myoglobin with troponin offers optimal management benefits.
- Implementing cardiac marker testing leads to more efficient patient care and cost savings.
Abstract:
Cardiac markers can be used effectively for diagnosing, triaging, treating and monitoring of patients with acute coronary syndromes. Therefore, in accord with the recommendation of the NACB and IFCC, the use of myoglobin and troponins, especially troponin T (TnT) because of the broader data base, are well-suited to fulfil the needs of management of acute coronary syndromes. The present paper reviews recent data to evaluate their relevance, especially in deciding the treatment of patients with non-ST elevation acute coronary syndromes. Furthermore, economic studies show that the use of even the more expensive diagnostics is associated with tremendous cost savings due to more efficient patient management. The use of cardiac markers therefore represents a valuable tool in the management of these patients. The best combination is that of myoglobin with troponin.